Quick Answer
Esperion Therapeutics, Inc. reported Total Assets of $465.89 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +35.5% in Total Assets from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $19.53 million | Q3 2013: $86.58 million | Q1 2014: $70.22 million | Q2 2014: $69.29 million | Q3 2014: $60.53 million | Q1 2015: $325.22 million | Q2 2015: $315.96 million | Q3 2015: $306.39 million | Q1 2016: $286.04 million | Q2 2016: $277.47 million | Q3 2016: $263.79 million | Q1 2017: $214.61 million | Q2 2017: $185.24 million | Q3 2017: $313.09 million | Q1 2018: $244.19 million | Q2 2018: $210.88 million | Q3 2018: $174.03 million | Q1 2019: $236.48 million | Q2 2019: $308.81 million | Q3 2019: $255.27 million | Q1 2020: $179.64 million | Q2 2020: $330.35 million | Q3 2020: $250.97 million | Q1 2021: $278.61 million | Q2 2021: $280.46 million | Q3 2021: $225.26 million | Q1 2022: $342.85 million | Q2 2022: $303.98 million | Q3 2022: $312.83 million | Q1 2023: $251.82 million | Q2 2023: $234.63 million | Q3 2023: $221.31 million | Q1 2024: $373.06 million | Q2 2024: $352.32 million | Q3 2024: $314.11 million | Q1 2025: $324.03 million | Q2 2025: $347.09 million | Q3 2025: $364.02 million.
- Over the full 14 years of available data (2012 to 2025), Esperion Therapeutics, Inc.'s Total Assets has grown by 6,271.1%.
- Historical annual values: Fiscal year 2025: $465.89 million | Fiscal year 2024: $343.82 million | Fiscal year 2023: $205.80 million | Fiscal year 2022: $247.94 million | Fiscal year 2021: $381.59 million | Fiscal year 2020: $353.26 million | Fiscal year 2019: $214.45 million | Fiscal year 2018: $143.45 million | Fiscal year 2017: $277.84 million | Fiscal year 2016: $245.21 million | Fiscal year 2015: $295.57 million | Fiscal year 2014: $143.28 million | Fiscal year 2013: $78.29 million | Fiscal year 2012: $7.31 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: